From Grants to Family Offices: Building a Unified Financing Strategy in Biotech
In this Denatured episode, Jennifer C. Smith-Parker speaks to Ram May-Ron, managing partner at FreeMind Group, and Ravi Kiron, managing director at Biopharma Strategy Advisors. We'll discuss how best to tailor an investment approach of both nondilutive funding and family offices to overcome the drug development valley of death.
Host
Jennifer Smith-Parker, Director of Insights, BioSpace
Guests
Ram May-Ron, Managing Partner, FreeMind Group
Ravi Kiron, Managing Director, Biopharma Strategy Advisors
Disclaimer: The views expressed in this discussion by guests are their own and do not represent…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.